Angeles Wealth Management LLC Sells 104 Shares of Becton, Dickinson and Company (NYSE:BDX)

Angeles Wealth Management LLC cut its stake in shares of Becton, Dickinson and Company (NYSE:BDXFree Report) by 5.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,788 shares of the medical instruments supplier’s stock after selling 104 shares during the period. Angeles Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $436,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Mendel Money Management raised its holdings in Becton, Dickinson and Company by 3.0% in the third quarter. Mendel Money Management now owns 1,536 shares of the medical instruments supplier’s stock worth $397,000 after purchasing an additional 45 shares in the last quarter. CWM LLC grew its stake in shares of Becton, Dickinson and Company by 0.7% in the fourth quarter. CWM LLC now owns 6,303 shares of the medical instruments supplier’s stock worth $1,537,000 after acquiring an additional 46 shares during the last quarter. S.A. Mason LLC grew its stake in shares of Becton, Dickinson and Company by 3.5% in the fourth quarter. S.A. Mason LLC now owns 1,420 shares of the medical instruments supplier’s stock worth $346,000 after acquiring an additional 48 shares during the last quarter. Edge Capital Group LLC grew its stake in shares of Becton, Dickinson and Company by 3.1% in the fourth quarter. Edge Capital Group LLC now owns 1,573 shares of the medical instruments supplier’s stock worth $384,000 after acquiring an additional 48 shares during the last quarter. Finally, Mitchell Mcleod Pugh & Williams Inc. grew its stake in shares of Becton, Dickinson and Company by 1.3% in the fourth quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 3,951 shares of the medical instruments supplier’s stock worth $963,000 after acquiring an additional 49 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors.

Becton, Dickinson and Company Trading Up 0.2 %

Shares of NYSE:BDX opened at $240.63 on Friday. The stock has a market capitalization of $69.54 billion, a price-to-earnings ratio of 53.00, a PEG ratio of 2.10 and a beta of 0.44. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. The stock’s 50-day simple moving average is $235.77 and its two-hundred day simple moving average is $237.98. Becton, Dickinson and Company has a 52-week low of $224.00 and a 52-week high of $287.32.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last announced its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.20. The business had revenue of $5.05 billion for the quarter, compared to analysts’ expectations of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same period last year, the firm posted $2.86 earnings per share. Analysts expect that Becton, Dickinson and Company will post 13.03 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.58%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Insider Transactions at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the sale, the senior vice president now owns 2,276 shares of the company’s stock, valued at approximately $542,348.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael David Garrison sold 1,715 shares of Becton, Dickinson and Company stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the sale, the executive vice president now directly owns 5,381 shares in the company, valued at approximately $1,252,750.61. The disclosure for this sale can be found here. Insiders have sold 8,597 shares of company stock valued at $2,028,786 over the last quarter. 0.31% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. The Goldman Sachs Group assumed coverage on Becton, Dickinson and Company in a research note on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price on the stock. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Barclays increased their target price on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research note on Monday, May 6th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $280.17.

Get Our Latest Report on Becton, Dickinson and Company

About Becton, Dickinson and Company

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

See Also

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.